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Abstract 
The EQ-5D-5L is a generic quality of life (QOL) measure widely used 
throughout the world, which has the advantage that it allows health state 
preferences to be elicited.  
Aims: To examine if:  
a) Variation in the standardised reference period for EQ-5D-5L from 
“today” to “the last month” had a minimal clinically meaningful 
difference.  
b) EQ-5D-5L had convergent validity with a multidimensional pain 
measure in quantifying the impacts of pain. 
Methods: As part of a larger study into the effectiveness and efficiency of 
care pathways for persistent oral facial pain (POFP) 
(http://research.ncl.ac.uk/deepstudy) participants with POFP (n=100) 
completed two versions of the EQ-5D-5L at the same time with different 
reference periods (‘Today’ versus ‘Last month’). Participants also completed 
the first section of the West-Haven Yale Multidimensional Pain inventory (v3) 
to assess convergent validity.  
Two-tailed non-parametric inferential statistics, intra-class correlation 
coefficients (ICC), and within subject change scores were used to compare 
the two EQ-5D-5L versions. Convergent validity was assessed using 
Spearman Rho correlation coefficients. 
Results: Health state valuations were significantly different (p<0.01), and 
there was good similarity between the two versions ICC 0.86 (95%CI 0.79-
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0.91). The within-subject mean change was 0.03 (95%CI 0.01-0.06). For 
convergent validity all relationships were significant (p<0.05), and in the 
expected directions. 
Conclusion: EQ-5D demonstrates sufficient convergent validity to be used 
with POFP and a change in the standard reference period may be 
unnecessary if a multidimensional pain measure is also used. 
 
Keywords: Quality of Life, Persistent orofacial pain, EQ-5D, Facial pain, 
Pain, Outcome  
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Introduction 
 
Persistent (chronic) pain affecting the orofacial region is defined as pain 
lasting greater or equal to three months (1). It can be caused by any one of a 
heterogeneous group of conditions, which are either neuropathic, 
musculoskeletal, or neurovascular in origin (2). Given the heterogeneity of 
these conditions it has been necessary to construct instruments that measure 
the multidimensional nature of the biopsychosocial effects that persistent 
(orofacial) pain can exert. One of the most frequently used multidimensional 
instruments in persistent orofacial pain (POFP) over the last three decades is 
the West Haven Yale Multidimensional Pain Inventory (3).  
 
Perhaps unsurprisingly, given the need for multidimensional pain inventories, 
POFP is known to affect oral health related quality of life (OHRQOL) and exert 
psychosocial impacts on sufferers (4-11). Only limited data exist on using 
generic quality of life (QOL) measures with the group of conditions comprising 
POFP (5, 9, 12-22) with the majority of these studies using the 36-item short 
form health survey (SF-36 (23)) (5, 9, 12-15, 17, 19-21) and only four studies 
using the EQ-5D to examine QOL in Trigeminal neuralgia amongst other 
conditions producing pain elsewhere in the body (11, 16, 18, 22).  
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The predominant use of condition, or disease-specific, OHRQOL measures in 
POFP is understandable given the advantages these instruments possess in 
terms of sensitivity and specificity for the impacts of the particular condition or 
disease (24-26), but it also means that, despite some conversion formula 
being suggested (27), it is difficult to compare the impact of POFP conditions 
with other (pain) conditions presenting elsewhere in the body. There are also 
currently no population norms available for the most frequently used 
OHRQOL measure in POFP the Oral Health Impact Profile (28) and therefore 
valuations of particular (oral) health states are currently impossible. 
 
Both the SF-36 and the EQ-5D (29) have the capacity to generate health-
state valuations from population norms although the former does so through a 
recently devised estimation process. Whilst the estimation process developed 
is robust there are concerns over the reliability of the tool amongst more 
severe conditions (30).  Given recent OHRQOL data this is the situation 
expected in POFP (6). In contrast the EQ-5D has been shown to perform well 
in differentiating between severe health states (31). The EQ-5D was 
specifically designed to estimate health state preferences as the basis of 
calculation of quality adjusted life years (QALYs) and has extensive 
population norm data available from across Europe (32). QALYs are 
especially important in chronic conditions as they take into account both the 
quality, and quantity, of life and thereby permit comparison of different health 
care interventions’ using a common and consistent numeraire. 
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The latest iteration of EQ-5D, the EQ-5D-5L, examines limitations in five 
dimensions: mobility, pain/discomfort, self-care, anxiety/depression, and usual 
activities, by asking respondents to indicate their level of disability on a five 
item ordinal scale, with lower scores equating to less disability in that 
dimension. The standard reference period for the response is the 
respondent’s “own health state today”. Despite widespread use across a vast 
variety of other conditions the EQ-5D has received scant attention in the 
POFP literature (11, 16, 18, 22) and has never been employed with a 
heterogeneous group of POFP. The heterogeneity of POFP conditions means 
they can impact differently both at the individual patient level but also at a 
condition-level and may do so in a fluctuating manner over short periods of 
time. This study, therefore, aimed to examine whether: 
a) Variation in the standardised reference period for EQ-5D-5L from 
“today” to “the last month” produced minimum clinically meaningful 
differences (also known as the minimally important difference) in 
responses.  
b) EQ-5D-5L had convergent validity with a multidimensional pain 
measure  (West-Haven Yale Multidimensional Pain Inventory [MPI] (3)) 
in quantifying the impacts of POFP. 
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Methods 
This study is part of the larger and ongoing DEEP study (Developing Effective 
and Efficient care pathways in chronic Pain 
htttp://research.ncl.ac.uk/deepstudy) and received ethical approval from the 
UK NHS National Research Ethics Service Committee Leeds West (Ref 12-
YH-0338). The DEEP study protocol is available on open access and contains 
full details of the methods of the overall programme of research (33). Details 
relevant to this particular part of the DEEP study are included below. 
 
Participants and procedures 
A convenience sample of consecutive patients was drawn from the 
community (general medical and dental practice) and hospital (specialist 
dental or medical) practice using the centres recruiting for the DEEP study 
(33). Consecutive, consenting, patients presenting with POFP defined as pain 
affecting the orofacial region for greater than or equal to three months were 
screened for eligibility using two validated screening instruments (34, 35). 
Patients were eligible if the screening indicated that the origin to their 
persisting pain was either of a musculoskeletal, neurological, or combined 
musculoskeletal/neurological origin (35) (34). Exclusion criteria were that the 
patient: lacked sufficient comprehension of the English language to complete 
the questionnaires or give informed consent; was less than eighteen years 
old; screened as only having Dentoalveolar pain (35). 
Eligible patients were invited to participate and all gave written informed 
consent. All patients enrolled in the study received a structured baseline 
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interview where the instruments used in the study were explained to them in a 
standardised fashion to ensure their comprehension. Patients then completed 
the instruments in their own time and sent them back in prepaid envelopes to 
the study team. Missing data identified within either instrument were followed 
up by phone-call with the participant and entered as appropriate to the 
participant’s verbal response prior to calculating summary scores. 
 
Measures and instruments 
Patients were issued with several questionnaire booklets in a standardised 
numerical order. Two of these questionnaire booklets are relevant to this 
particular study: one booklet contained the EQ-5D-5L, and the other booklet 
contained section one (severity, interference, life control, affective distress, 
support) of the multidimensional pain inventory version 3 (MPI)  (3). Section 
one of the MPI contained the constructs of interest to test the convergent 
validity of the two versions of EQ-5D. 
 
The EQ-5D-5L booklet had the EQ-5D-5L presented twice in a standardised 
order: once using the standard reference period of “…health state today” 
(TODAYQ), and the other iteration with the new reference period “…health 
state over the last month” (MONTHQ). All the other aspects of EQ-5D-5L 
remained unaltered (a good summary of EQ-5D can be found at 
http://www.euroqol.org). 
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Section one of the MPI was unaltered from the standard version 3 of the 
instrument. Both instruments’ summary scores were calculated in the 
standardised fashion as described in the literature (29, 36). The MPI summary 
scores were calculated using the item-response theory method (Rasch model 
of Version 3 of the MPI software and instrument). The health state valuations 
for EQ-5D-5L were calculated by firstly concatenating the response codes to 
each item to produce a final health state summary score ranging from 11111 
(least disability) to 55555 (worst disability). This health state summary score 
was then compared to normative data sets to generate a health state 
valuation: ranging from -0.59 (state worse than death) through 0 (equivalent to 
being dead) up to 1 (perfect health) using the crosswalk data set for the UK 
population norms (37).  
Data analysis 
An a priori power calculation determined that in order to detect a small to 
moderate effect size of 0.3 (38), with 80% confidence of detecting a type I 
error of 5%, using paired, two tailed, inferential statistics, ninety patients 
would be required to complete the two versions of the EQ-5D questionnaire. 
One hundred patients were therefore recruited to allow for a 10% drop-out 
rate which was based on the authors’ previous experiences with this type of 
research. 
 
All data analyses were conducted with STATA, Release 12 (Stata Statistical 
Software, College Station, TX, USA). The main aim of the analysis was to 
examine differences between the two versions of the EQ-5D-5L and compare 
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these to the clinically meaningful difference (CMD) as determined in the 
literature. The secondary aim of the analyses was to examine the two 
versions’ convergent validity with the outputs from section one of the MPIv3.  
 
Simple descriptive statistics were used to help present and examine the data. 
Wilcoxon signed rank tests were used to test for significant differences 
between the health state valuations generated by the two different versions of 
EQ-5D-5L. An intraclass correlation coefficient (ICC 2,1) was calculated in 
order to examine the correlation between all possible orderings of pairs of 
responses between TODAYQ and MONTHQ health state values. The within-
subject change was then examined using the method described by Sutinen 
and colleagues for a similar reference period study (39); that is subtracting the 
MONTHQ health state value from the TODAYQ value and comparing this 
value to a point estimate (0.07) for the CMD (40). The CMD was defined as 
the smallest amount of change that patients perceive as beneficial or that 
would suggest a change in management (40). The point estimate used in this 
study for the CMD was derived from Walters and Brazier’s research (40) 
which employed both distribution and anchor based methods in a secondary 
analysis of large data set from a range of different conditions in order to 
calculate EQ-5D’s CMD. This more generic CMD is similar to the CMDs 
identified in more recent, condition specific, studies on cancer, inflammatory 
bowel disease, and post traumatic stress disorder (41-43), but lower than 
those identified in spinal surgery (44-46). The correlation between the health 
state values and the subscales of the MPI were also examined using a 
Spearman’s Rho correlation coefficient. 
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Results 
A total of 100 patients were recruited to the study. Of these 100 patients five 
failed to fully complete both questionnaires, all of whom were male. There 
was no significant difference between those who did or did not complete the 
study on the basis of age, gender, or diagnostic group (p>0.2). Of those failing 
to complete both questionnaires one individual did so through non-response 
to the original distribution and follow-up and the remainder did so through 
non-response to the telephone follow-up of missing data on the 
questionnaires. All had too much missing data to allow any form of imputation. 
There were no missing data amongst the remainder of the sample (n=95) who 
completed both questionnaires for this study. 
 
Table 1 demonstrates the sample’s demographics and origin of pain. The 
majority of the sample were female (n=77, 81%), and had pain of a combined 
origin (n=52, 55%).  Figure 1 shows the respondents’ scores to the five 
dimensions (items) of the EQ-5D-5L by the reference period of the question. 
The mean difference between ‘Today’ and ‘Month’ health state valuation was 
0.03 (95% CI 0.02-0.05) and the difference exceeded the CMD for 21 
individuals in the sample. The difference between ‘Today’ and ‘Month’ 
valuations for those who exceeded the CMD was 0.07-0.74 (mean 0.18).  
There was a statistically, but not clinically, significant difference (P<0.001, 
effect size 0.14) between the ‘Today’ health state valuation (Mean 0.70, 
95%CI 0.65-0.74) and the ‘Month’ health state valuation (Mean 0.66, 95%CI 
 12 
0.62-0.71).  The ICC showed good similarity between scores 0.86 (95%CI 
0.79-0.91) between the two versions of EQ-5D-5L. When the within subject 
variance was examined the mean raw difference was 0.03 (95%CI 0.01-0.06). 
 
The correlation coefficients for the Spearman’s Rho calculations between the 
subscales of the MPI and the health state valuations are shown in Table 2. All 
correlations were significant and in the expected direction. The majority of 
coefficients were of moderate or large size (38). 
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Discussion 
This was the first study, using POFP as a group of conditions, to assess the 
variation in the standardised reference period for the EQ-5D-5L and to 
examine whether this measure has convergent validity with a 
multidimensional pain measure, MPI, when quantifying the impacts of POFP.  
 
The results indicate a statistically significant difference in the health state 
valuation between the reference points ‘Today’ and ‘Month’, illustrating the 
difficulties in capturing the impact of persistent pain using a standardised 
generic QOL measure. The magnitude (effect size) of the statistically 
significant difference between the two health state values was, however, small 
and therefore not likely to be clinically relevant. When the point estimate of the 
mean raw difference between the two reference points is examined it too is 
below clinically meaningful difference for EQ-5D in the literature (0.07 (40)). 
The difference in scores between the two reference periods was related to 
fluctuations in the dimensions of pain and activity levels with the month 
reference period capturing greater levels of impact than the today reference 
period. This is consistent with the known fluctuation of symptoms, and 
therefore impact, of several of the conditions comprising POFP (6, 47). 
 
EQ-5D-5L demonstrated good convergent validity with the condition specific 
measure, the MPI, suggesting that EQ-5D-5L is an appropriate tool for use 
with POFP. If EQ-5D-5L is to be used with POFP using the standard “today” 
reference period there is a conscious trade-off to be considered. This trade-off 
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is between generating generic cross-condition/disease QALYs that can be 
compared, versus losing detail on the level of impact of POFP thereby 
potentially slightly underestimating its impact. At present the authors would 
suggest to compensate for this loss of detail by utilising an instrument such as 
the MPI alongside the EQ-5D in order to help capture the impact over a longer 
period of time. The MPI clearly also captures some additional data beyond the 
scope of the EQ-5D given the lower correlation coefficients in its social 
support domain. Its concomitant use may, therefore, help further explain the 
reasons behind the impact of POFP, but would have to be weighed against 
the risk of attrition and or acquiescence bias with the use of more questions. 
Given the data presented in this paper the authors feel the advantages of 
using the standard reference period of “Today” outweigh the potential 
disadvantages as long as they are recognised as a limitation in any data 
produced using this method. 
 
This study had some limitations. The study assessed a broad heterogeneous 
group of patients who had not received a specialist diagnosis. This limitation 
may also be viewed as a strength however, as the aim of the study was to 
apply EQ-5D-5L to POFP not a particular subset of the disorders. The study 
also did not assess whether the EQ-5D-5L measure was responsive to 
change. It is possible that with the ongoing prospective data collection in the 
DEEP study we will be in a position to provide an answer to this question and 
also a POFP specific CMD. We did, however, purposefully choose one of the 
more generic, CMDs in the literature to compare the performance of the two 
versions of the instrument against in order to carefully examine the difference 
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made by the change in reference period. It is, however, conceivable that 
perhaps this is not a stern enough test, that is the CMD for POFP is actually 
lower than this, but we feel it is more likely that the CMD for POFP is higher 
than this. One further limitation of our method is the standardised order in 
which we presented the two versions of EQ-5D. We chose to do this so it was 
absolutely clear to the participants that the two questionnaires were not just 
duplicates of each other and had a subtle difference. We accept, however, 
that methodologically it might have been stronger to randomise the order. 
 
Comparing the health state valuation of POFP in this study to other conditions 
is somewhat difficult, as data on other conditions’ health state valuation, at the 
time of writing, currently exists only through the use of EQ-5D-3L. This said 
the EQ-5D-5L values used in this study are those cross-walked from the EQ-
5D-3L (37) so are somewhat equivalent. Our estimates (today reference 
period) of health state valuations for POFP are comparable to other persistent 
(chronic) health states such as arthritis, and depression, but less than 
conditions such as back, pain, stroke and Parkinson’s (37). Examining studies 
that have also used EQ-5D with singular entities (Trigeminal neuralgia (22), 
Inferior Alveolar and Lingual nerve damage (11)) comprising part of the group 
of POFP conditions it would appear that we are broadly comparable to the 
range they identified (0.56-0.68). Our confidence interval for the health state 
valuation of POFP is also less than that of the UK health population norm 
(0.75-0.94) for the age groups 25-75+. 
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Conclusion 
The impact of POFP on an individual’s quality of life is captured using EQ-5D-
5L’s standard “Today” reference period and the instrument possesses 
sufficient convergent validity to be used with POFP. Results from EQ-5D-5L 
using the standard reference period may tend towards a slight underestimate 
of the actual impact of POFP on individuals’ QOL and therefore it is advisable 
to use another multidimensional pain measure in conjunction that possesses 
longer reference period to compensate for this. 
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Figure 1 - Respondents’ mean scores by dimension and reference 
period of EQ-5D-5L 
 
*p<0.05 
***p<0.001 
Error bars give standard error of the estimate 
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Table 1 – Sociodemographic of sample and origin of pain 
Variable Gender  Cohort  
Male  
(n=18) 
Female 
(n=77) 
Mean age (SD) 52 (17) 52(16) 52 (16) 
Origin of pain as 
determined by screening 
(Hapak et al 1994; 
Gonzalez et al 2011)  
   
Musculoskeletal  
% (n) 
22 (4) 13 (10) 15 (14) 
Neuropathic/Neurovascular  
% (n) 
28 (5) 31 (24) 30 (29) 
Combined  
% (n) 
50 (9) 56 (43) 55 (52) 
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Table 2 – Spearman Rho correlation between dimensions of MPI and summary score of EQ-5D-5L (Month reference period 
“MONTHQ” and standard Today reference period “TODAYQ”) 
    EQ-5D-5L summary scores MPI Dimension summary scores 
    MONTHQ  TODAYQ  Pain severity  Interference Life control  Affective distress Support 
    
Coeff 
(95% CI) 
Coeff 
(95% CI) 
Coeff 
95% CI 
Coeff 
95% CI 
Coeff 
95% CI 
Coeff 
95% CI 
Coeff 
95% CI 
EQ-5D-5L 
summary 
scores 
MONTHQ 
1 
  
0.87*** 
(0.81, 0.91)  
-0.68*** 
(-0.78,-0.56)  
-0.48*** 
(-0.63,-0.31)  
0.42*** 
(0.23,0.57)  
-0.46*** 
(-0.61,-0.28)  
-0.26* 
(-0.44,-0.06)  
TODAYQ  
  
  
1 
  
-0.67*** 
(-0.77,-0.54)  
-0.49*** 
(-0.63,-0.32)  
0.43*** 
(0.25,0.58)  
-0.50*** 
(-0.64,-0.33)  
-0.29** 
(-0.47,-0.10)  
Coeff – Spearman’s rho correlation coefficient 
95% CI – 95% Confidence interval of coeff. 
***p=0 
**p<0.01 
*p<0.05 
 
 
 
 
